In another study of 9 patients with SGAs (immunonegative for GH, ACTH, PRL, and TSH and positive for LH, FSH, and/or α-subunit and >50% cells expressing D2R) with postoperative residual tumor present, 3 mg/week of cabergoline caused a >25% tumor volume reduction in six of the nine patients after 6 months (45). The gene discussed is PLOD1; the disease is neoplasm.